Low-GI Claims Across Borders: Why One Pack Cannot Carry the Same GI Statement in Every Market
Low-GI Claims Across Borders: Why One Pack Cannot Carry the Same GI Statement in Every Market
This note is written for importers, regulatory affairs staff and category buyers who are taking a low-GI range into more than one destination market, and who keep running into the same surprise: the phrase "low GI" is an ordinary commercial statement in one country, an unregulated space with hard limits in a second, and effectively unavailable in a third. That is not a technicality. It decides how many artwork versions you print, which evidence file travels with each version, and whether a range launches on one date or has to be staged market by market.
Most low-GI sourcing conversations start with the product and move to the evidence: what is the GI value, which method, which laboratory. Those questions are the right ones. This note starts one step earlier, with the question that has to be answered before any of them: in the market I am shipping into, what is the legal standing of a glycaemic index statement on a pack? The answer differs materially between the four markets most often discussed together.
1. Four markets, four different legal positions
It helps to name the four positions precisely, because they are frequently treated as one thing and they are not.
Canada has taken a negative position. Health Canada published a position against the use of GI claims on food labels in 2011, holding that including a GI value on eligible products would be misleading and would not add value to nutrition labelling.
The European Union has a regulatory gap. Under Regulation (EC) No 1924/2006, a nutrition claim is an indication about the energy value or the presence, absence or proportion of a nutrient. A health claim is an indication affirming, suggesting or implying a relationship between a food or one of its components and health. A glycaemic index value fits neither definition cleanly, because it describes the rate at which available carbohydrate is metabolised rather than either a nutritional property or a health effect. The practical result is that a GI value is neither expressly permitted nor expressly prohibited, and the boundary is drawn at the moment the statement starts implying a benefit.
The United States has no GI-specific rule. The FDA has not established a dedicated regulatory requirement for glycaemic index claims. The responsibility sits with the party responsible for the label, which means the obligation to substantiate a GI statement rests inside your organisation rather than with a regulator who will review it in advance.
Japan has no GI regulation, and has a marked market anyway. No Japanese legislation specific to GI claims exists. The government has encouraged research into the relationship between GI and health. In the absence of a domestic rule, products carrying GI marks obtained through overseas certification bodies are already present on the market, so the practice has moved ahead of the framework.
Read across those four, the pattern is clear. In one market a GI statement is contested in principle. In a second it is unregulated but bounded. In a third it is unregulated with a named liable party. In a fourth it is unregulated with a de facto commercial practice already in place. Only one of these is a permission, and none of them is a permission you can reuse.
2. Canada is the hard case, and the reason matters
Canada deserves more than a mention, because the objection is substantive and it will come up again during your review. Three arguments were advanced: that the GI measure does not have sufficient accuracy and precision for labelling purposes; that GI is a ratio and therefore does not vary with the amount of food consumed, whereas glycaemic response does; and that an emphasis on GI could lead to food choices inconsistent with national dietary guidance.
Each of those has been contested in the peer-reviewed literature, and the answer to the third point is instructive. The concern about a low-GI product that is high in fat or sodium is legitimate, and the proposed remedy in the literature is not to abandon GI but to attach nutrient profiling criteria to it, applying the kind of conditions already used to support health claims, so that a product must be limited in sodium, saturated fat and trans fat, and meet a minimum contribution of vitamins or minerals, before it is allowed to carry the statement.
That is the direction of travel most observers in this field expect: if GI labelling ever becomes usable in Canada, it will arrive attached to a nutrient profile rather than as a bare number. For an importer today, the practical reading is simpler than the history: build the product so that a nutrient profile can be attached to it later. A formulation that is low glycaemic, moderate in sodium, controlled in saturated fat and meaningful in micronutrients can answer the question whenever the framework moves. A formulation that is low glycaemic and nothing else will have to be reformulated, relabelled and re-reviewed.
3. The European gap is narrower than it looks
The EU position is regularly summarised as "unregulated", and that summary causes most of the problems. The two conditions that actually govern the use of a GI value in the EU are straightforward.
First, the duty to measure. The GI must be determined for the specific product as it is communicated, using the internationally recognised method set out in ISO 26642:2010. This matters more than it appears, because GI varies widely within a single food category depending on variety, processing and preparation. A value measured on one production run, or on a different batch structure, or on a product that is subsequently reformulated, does not carry over. The value belongs to the item in the pack.
Second, the prohibition on implied benefit. Operators are strictly prohibited from implying, directly or indirectly, that the GI value itself confers a nutritional or health benefit. The moment a statement stops being a measurement and becomes a promise, it is a health claim, it falls under the authorisation requirements of Regulation (EC) No 1924/2006, and it must appear in the EU Register of Nutrition and Health Claims. As things stand the Register does not contain an authorised glycaemic index claim, so there is no wording to borrow.
The practical line is therefore straightforward even though the law is untidy: the number can travel, the promise cannot. Printing a measured value with its method is a different act from printing "balances your blood sugar", and only the first one sits outside the authorisation system. If your artwork was written by someone optimising for impact rather than for defensibility, this is where it will fail, and it usually fails late, after artwork is locked and freight is moving.
There is one further constraint worth naming here, because it applies everywhere and not only in the EU. Food must not carry disease treatment or prevention claims. Wording of that kind is a regulatory event rather than a marketing decision, and phrases such as for diabetics or lowers blood sugar belong to the prohibited category in essentially every market a low-GI range will reach.
4. The United States inverts the burden of proof
The US position is easy to misread as the most permissive of the four, and in practice it is the one that puts the most weight on the importer. With no dedicated FDA requirement, there is no advance approval step and no regulator who will sign off on your wording before launch. The substantiation obligation stays with the party responsible for the label. If the statement turns out to be unsupported, the person who cannot answer for it is the one who put it on the pack.
What fills the space that a regulator would otherwise occupy is third-party review. Commercial bodies in the United States assess glycaemic index statements and issue their own marks, a private gate rather than a government one. Such a mark is useful and worth having, but it should be described accurately: an assessment conducted by a non-governmental body, not a regulatory approval. Treating the two as interchangeable is how a buyer ends up believing a claim has been endorsed when it has only been reviewed.
For an importer the operative question in the US is therefore not "is this permitted" but "what happens to me if this is challenged". The answer depends on three things you can control: whether the value was measured under a stated method, whether the report is specific enough to the item on the shelf, and whether the wording on the pack describes a property of the food rather than an effect on the person eating it.
5. Asia as a useful contrast
Japan shows what happens when a market has no rule but does have a shelf. With no domestic GI legislation and no approval mechanism, the visible result is a range of products carrying marks obtained through overseas certification bodies. Nobody in Tokyo approved those marks, and they are on the shelf anyway, because the practice arrived before any rule did.
Singapore shows the opposite case. Under the Healthier Choice Symbol scheme, a low GI claim is permitted for specified food categories including cereals, legumes, nuts and seeds, and convenience meals. The claim is not free-standing; it sits inside a wider scheme with defined nutritional criteria and a defined assessment process. That is the structure this note has been describing, applied rather than debated.
Australia and New Zealand remain the most mature reference points, with a dedicated test method standard and explicit provisions in the food standards code for GI claims. That ground has been covered separately in this series and is not repeated here.
The pattern across all of them is that where a market has decided how to handle a GI claim, the handling is specific and category-based; where it has not, the handling is decided by whoever is willing to carry the risk. For a supplier, that second situation is not an opportunity, it is an unmanaged liability that happens to have no regulator attached to it yet.
6. Six questions that decide how many artwork versions you need
These are the questions to put to a supplier before the print run is committed, because the answers determine the artwork count and the evidence file structure. They are phrased so that a regulatory affairs colleague can ask them without a technical translator present.
1. In each destination market on our list, do you hold a written position on what may be printed about glycaemic index, and who is the responsible party for the label?
2. How many artwork versions does the current pack structure require, and does each version carry the method reference?
3. Is the GI value on the pack tied to a specific report number for a specific formulation, and does that report travel with the commercial file?
4. If the formulation changes, which artwork versions are withdrawn, and who is notified in each market?
5. Can you supply a per-market claim summary stating what is measurable, what is certificated, and what is not permitted?
6. Who signs off on label wording in each market, and is that role named in the file pack?
Question six carries the most information about how a supplier actually operates. A supplier who cannot name the responsible party per market has not made the decision, and the decision will be made late, by whoever is under time pressure at the port.
7. What Detective No.55 would put in front of you on this
For orientation, here is what we would send an importer working across several markets. GI test reports with stated methods and citable report numbers for each claim-bearing line, measured to WS/T 652-2019, the national standard for determining the glycaemic index of foods, which specifies the human clinical trial approach, and to ISO 26642:2010 where the destination market expects the international reference. Testing is performed in a laboratory holding both CMA and CNAS recognition, and the method and the laboratory are two separate questions with two separate answers. The claim system is operated with certification bodies authorised within the Chinese national framework by CNCA, so the domestic certification route and the overseas one are structured rather than improvised.
Alongside the measured values, we work per formulation rather than per brand, because that is the unit at which a GI value is valid and therefore the unit at which a claim can be defended. On the nutrition side of the question, the range is built so that a nutrient profile can be attached to any low-GI claim without reformulation: controlled sodium, controlled saturated fat, no trans fat, dietary fibre and micronutrient content stated on the pack. That is the property that makes a product resilient to whichever market decides to attach conditions to a GI claim in future.
The development work behind those numbers is built with medical specialists and research institutions in a joint low-GI research centre, with Dr. Liu Rui advising on the low-GI product work. Tang Yishen, the founder, came from senior retail leadership rather than from manufacturing, which is one reason the evidence side was built before it was needed rather than assembled to answer a buyer. The range covers staples, bakery, snacks and drinks, across more than forty product lines and more than one hundred specifications, and its products have reached over ten thousand retail terminals in China, with sales leadership in offline low-GI bakery channels and in low-GI apple crisp.
On format and logistics, the range is built around dry, ambient, long-life products, because that combination keeps the documentation, the freight plan and the shelf-life schedule aligned across every destination market rather than only the one you know best. The frozen apple crisp lines are specified with the BRC FOOD certification held by the Shanxi Zhongkang facility, and produced by freeze-drying rather than frying. The manufacturing base is a clean workshop rated to ten thousand particles per cubic metre. Across the range the food safety management system certifications held per production line include FSSC 22000 on one line and ISO 22000 with HACCP plus export filing on another.
8. The honest version
We are not going to tell you that one pack works across every market, because the regulatory positions described above make that untrue. We will not draft your submissions for a specific jurisdiction or state your registration timetable, because those obligations and timetables sit with the party placing the food on that market, and any version of that produced by a supplier is a guess dressed as a service. Nor will we describe a third-party mark as a regulatory approval, because it is not one.
What we can do is send the underlying evidence in a form that survives assessment: measured values with stated methods and citable report numbers, certificates with numbers, a per-line certificate index, per-lot documentation, the shelf-life schedule by line and format, a written change-control commitment that travels with the artwork, per-market claim summaries stating plainly what is measured and what is not permitted, product training plus technical tools so the GI data is presented the same way in every language version, third-party inspection support, and a written channel-conflict policy so the same buyer is not undercut elsewhere. Export capability documentation, including destination-market registration support, comes with it.
Ask which markets on your list are decided, which are open, and which are contested. That single question sorts most of the work into a sequence you can plan against, and it separates the decisions that belong to you from the ones that belong to your supplier.
